MS Infusions

NOVANTRONE is used to reduce relapses and disability in patients with the following forms of MS:

• Secondary (chronic) progressive
• Progressive relapsing
• Worsening relapsing-remitting

NOVANTRONE is not for patients with primary progressive MS.

NOVANTRONE is administered by infusion at an infusion center or a specially equipped doctor's office. It is given once every 3 months.

There is a lifetime limit of no more than 8-12 doses due to possible cardiac toxicity.

Common Side Effects with NOVANTRONE® Infusion Treatment

• Nausea
• Hair thinning
• Loss of menstrual periods
• Upper respiratory tract infection
• Bladder infections
• Mouth sores

This is only a partial list of possible treatment side effects. Please refer to individual patient medication guides for a full list. Always talk to your healthcare provider about any questions you may have about side effects.

Information referenced on 5/2/2011 from NOVANTRONE.COM
No conclusions regarding comparative safety or efficacy of products can be drawn based on this information.

	Here's what you can expect during a typical infusion procedure: Your temperature and vital signs are checked. An IV needle is inserted by a nurse, and the infusion begins. You can sit comfortably while the infusion takes place. Vital signs are checked again after the infusion is complete.

For more information on TYSABRI ^®, including Boxed Warning and Medication Guide, visit www.tysabri.com.

TYSABRI is a prescription medicine approved for adult patients with relapsing forms of MS to slow the worsening of physical disability that is common in patients with MS and decrease the number of flare-ups (relapses).

Because TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection that usually causes death or severe disability, TYSABRI is generally recommended for patients that have not been helped enough by, or cannot tolerate another treatment for MS.

TYSABRI does not cure MS and has not been studied for longer than two years or in patients with chronic progressive MS.

TYSABRI is administered by infusion at an infusion center or a specially equipped doctor's office. It is given once every 4 weeks.

In order to receive TYSABRI, you must be enrolled in the TOUCH ^® Prescribing Program, a restricted distribution program focused on safety.

The results of a 2-year study showed:

Reduced flare-ups:
TYSABRI reduced how often flare-ups occurred by 67% compared to 41% with placebo. The average number of flare-ups a person had each year was 0.22 for TYSABRI and 0.67 for placebo.

Slowed disability progression:
TYSABRI lowered the chance a person's physical disability would worsen by 42% compared with placebo (17% of people on TYSABRI had their physical disability worsen versus 29% on placebo).

Reduced the number of new active lesions:
97% of people taking TYSABRI had no new lesions that showed disease activity compared with 72% of people taking placebo. However, changes in MRI often do not relate to how your MS is progressing.

Potential Side Effects with TYSABRI ^® Infusion Treatment

• Progressive multifocal leukoencephalopathy (PML)
• Headache
• Pain including stomach, arms, legs, joints
• Vaginitis
• Feeling tired
• Depression and mood changes
• Hypersensitivity or allergic reaction
• Infection
• Nausea or diarrhea
• Rash or mouth sores

This is only a partial list of possible treatment side effects. Please refer to individual patient medication guides for a full list. Always talk to your healthcare provider about any questions you may have about side effects.

Information referenced on 5/2/2011 from TYSABRI.com
No conclusions regarding comparative safety or efficacy of products can be drawn based on this information.